Announcements Trials
Browse Landscape

Status

Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 3Cyclophosphamide 3fludarabine 2zanubrutinib 1tafasitamab 1resiniferatoxin 1pomalidomide 1duvelisib 1bismuth tripotassium dicitrate 1Tetracycline 1Specimen Handling 1Prednisone 1Patient Reported Outcome Measures 1Neuropsychological Tests 1Metronidazole 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interleukin-2 1Esomeprazole 1Clarithromycin 1CT-P10 1Biopsy 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, B-Cell, Marginal Zone × duvelisib × Clear all
NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Ruijin Hospital

Not yet recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡